CLINICAL TRIALS PROFILE FOR AEMCOLO

All Clinical Trials for AEMCOLO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04082780 ↗	Rifamycin in Minimal Hepatic Encephalopathy	Recruiting	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2	2019-09-01	This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
NCT04501380 ↗	Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)	Recruiting	Bradley A. Connor, M.D.	Phase 2	2020-06-30	Open label interventional randomized pilot study utilizing two dosing regimens of AEMCOLO. The goal of this study is to evaluate effectiveness of a novel antibiotic, AEMCOLO (Rifamycin SV MMX) in the treatment of Small intestinal bacterial overgrowth (SIBO).
NCT04501380 ↗	Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)	Recruiting	Bradley Connor	Phase 2	2020-06-30	Open label interventional randomized pilot study utilizing two dosing regimens of AEMCOLO. The goal of this study is to evaluate effectiveness of a novel antibiotic, AEMCOLO (Rifamycin SV MMX) in the treatment of Small intestinal bacterial overgrowth (SIBO).

Clinical Trial Conditions for AEMCOLO

Condition Name

Condition Name for AEMCOLO
Intervention	Trials
Cirrhosis, Liver	1
Gastrointestinal Disease	1
Gastrointestinal Infection	1
Hepatic Encephalopathy	1

Condition MeSH

Condition MeSH for AEMCOLO
Intervention	Trials
Liver Cirrhosis	1
Hepatic Encephalopathy	1
Brain Diseases	1
Gastrointestinal Diseases	1

Clinical Trial Locations for AEMCOLO

Trials by Country

Trials by Country for AEMCOLO
Location	Trials
United States	2

Trials by US State

Trials by US State for AEMCOLO
Location	Trials
New York	1
Virginia	1

Clinical Trial Progress for AEMCOLO

Clinical Trial Phase

Clinical Trial Phase for AEMCOLO
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for AEMCOLO
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for AEMCOLO

Sponsor Name

Sponsor Name for AEMCOLO
Sponsor	Trials
Hunter Holmes Mcguire Veteran Affairs Medical Center	1
Bradley A. Connor, M.D.	1
Bradley Connor	1

Sponsor Type

Sponsor Type for AEMCOLO
Sponsor	Trials
Other	2
U.S. Fed	1

Last updated: May 2, 2026

AEMCOLO (Rifaximin, 200 mg) Clinical Trials Update, Market Analysis, and 2029 Projection

What is AEMCOLO and what pipeline events matter commercially?

AEMCOLO is an oral prescription formulation of rifaximin (brand name: AEMCOLO) positioned for travelers’ diarrhea. The commercial narrative for AEMCOLO depends on (1) whether new trials expand indications, (2) whether competitors sustain efficacy and payer coverage advantages, and (3) whether manufacturing scale and price changes protect margin.

However, the prompt provides no trial-update dossier and no market baseline data for AEMCOLO. Under the operating constraint, a complete and accurate response cannot be produced without specific clinical trial results (stage, endpoints, dates), regulatory milestones, and current market performance inputs (revenue, unit sales, pricing, and payer coverage).

Output: none